Zynerba Pharmaceuticals has announced the start of the its Phase 2 STAR1 trial to assess the safety and effectiveness of ZYN002, a cannabiniol (CBD) gel for the treatment of adult epilepsy patients with refractory focal seizures.
“The dosing of the first patients in the STAR 1 clinical trial in adults with refractory epilepsy is a significant milestone for the company,” said Armando Anido, chairman and CEO of Zynerba, in a press release. “We are pleased by the pace of the clinical program for ZYN002.”
ZYN002 CBD gel is the first synthetic CBD formulated as a permeation-enhanced gel for transdermal (applied to the skin) delivery. It is also under development and in testing for osteoarthritis and Fragile X syndrome. Anido said top line results from all three trials can be expected during the first half of 2017.
The ZYN002 gel is